Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

### 144: Filer Information

Filer CIK 0001923805
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

**Submission Contact Information** 

Name Phone

E-Mail Address

### 144: Issuer Information

Name of Issuer Ventyx Biosciences, Inc.

SEC File Number 001-40928

662 ENCINITAS BLVD., STE. 250

Address of Issuer ENCINITAS CALIFORNIA

92024

Phone (760) 593-4832

Name of Person for Whose Account the Securities are To Be Sold Sandborn William J.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

### 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Securities
Common	Jefferies LLC 520 Madison Ave, 4th Fl New York NY 10022	10790	394374.50	56980000	04/28/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

ction Wnom	this Donor a Acquired	Amount of Securities  Acquired	Date of Payment	Nature of Payment *
	ition	otion Whom a Acquired	oftion Whom a Acquired Acquired	oftion Whom a Donor Securities Payment

Common	03/27/2019 Stock Options	Ventyx Biosciences	9676	03/27/2019 N/A
Common	02/26/2021 Stock Options	Ventyx Biosciences	636	02/26/2021 N/A
Common	02/26/2021 Stock Options	Ventyx Biosciences	478	02/26/2021 N/A

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Nothing to Report

# 144: Remarks and Signature

Remarks

Date of Notice 04/28/2023

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 12/19/2022

**ATTENTION:** 

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature William Sandborn

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)